These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33427377)

  • 21. Separation methods for nucleoside analogues used for treatment of HIV-1 infection.
    Pereira AS; Tidwell RR
    J Chromatogr B Biomed Sci Appl; 2001 Nov; 764(1-2):327-47. PubMed ID: 11817036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The ideal nucleoside/nucleotide backbone.
    Gallant JE
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S44-51. PubMed ID: 15319669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].
    Bonora S; Calcagno A; Gonzalez de Requena D; Bargiacchi O; Di Perri G
    Infez Med; 2006 Jun; 14(2):61-70. PubMed ID: 16891850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday.
    Li G; Yue T; Zhang P; Gu W; Gao LJ; Tan L
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33572409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure, Synthesis and Inhibition Mechanism of Nucleoside Analogues as HIV-1 Reverse Transcriptase Inhibitors (NRTIs).
    Yoshida Y; Honma M; Kimura Y; Abe H
    ChemMedChem; 2021 Mar; 16(5):743-766. PubMed ID: 33230979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase.
    Sofia MJ; Chang W; Furman PA; Mosley RT; Ross BS
    J Med Chem; 2012 Mar; 55(6):2481-531. PubMed ID: 22185586
    [No Abstract]   [Full Text] [Related]  

  • 27. Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues.
    Chevaliez S; Rodriguez C; Poiteau L; Soulier A; Donati F; Darty-Mercier M; Pioche C; Leroy V; Brodard V; Zoulim F; Brouard C; Larsen C; Semaille C; Roudot-Thoraval F; Pawlotsky JM;
    J Viral Hepat; 2019 Feb; 26(2):278-286. PubMed ID: 30339311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic.
    Tian L; Qiang T; Liang C; Ren X; Jia M; Zhang J; Li J; Wan M; YuWen X; Li H; Cao W; Liu H
    Eur J Med Chem; 2021 Mar; 213():113201. PubMed ID: 33524687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is hepatitis virus resistance to antiviral drugs a threat?
    Pawlotsky JM
    Gastroenterology; 2012 May; 142(6):1369-72. PubMed ID: 22537445
    [No Abstract]   [Full Text] [Related]  

  • 30. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase.
    Khan S; Attar F; Bloukh SH; Sharifi M; Nabi F; Bai Q; Khan RH; Falahati M
    Int J Biol Macromol; 2021 Jun; 181():605-611. PubMed ID: 33766591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in the design of nucleoside analogues as anti-HIV drugs.
    el Kouni MH
    Curr Pharm Des; 2002; 8(8):581-93. PubMed ID: 11945160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
    Bernardino de la Serna JI; Mora Rillo M; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():7-12. PubMed ID: 19195432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
    Menéndez-Arias L
    Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy.
    Balzarini J
    Biochem Pharmacol; 1999 Jul; 58(1):1-27. PubMed ID: 10403515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stealth nucleosides: mode of action and potential use in the treatment of viral diseases.
    Daifuku R
    BioDrugs; 2003; 17(3):169-77. PubMed ID: 12749753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance.
    Yin PD; Das D; Mitsuya H
    Cell Mol Life Sci; 2006 Aug; 63(15):1706-24. PubMed ID: 16715409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
    Barry M; Mulcahy F; Merry C; Gibbons S; Back D
    Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular Metabolism of Nucleoside/Nucleotide Analogues: a Bottleneck to Reach Active Drugs on HIV Reverse Transcriptase.
    Varga A; Lionne C; Roy B
    Curr Drug Metab; 2016; 17(3):237-52. PubMed ID: 26651972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.